Subjects will be randomized into one of two treatment arms following a minimum of four and maximum of eight cycles of induction treatment with anti-HER2 therapy.
Arm A subjects will receive the experimental therapy, palbociclib, in addition to their current anti-HER2 therapy and endocrine therapy.
Arm B subjects will continue to receive the anti-HER2 therapy and endocrine therapy.
It is expected that the addition of palbociclib to the first-line treatment of HER2 disease will delay the onset of therapeutic resistance and ultimately prolong the survival of patients with metastatic breast cancer.
The study is designed to treat the subset of patients with HER2+ disease who are also hormone receptor-positive (HR+). It is also expected that palbociclib will modulate the endocrine resistance in HER2+/HR+ disease and potentiate the benefits of anti-HER2 therapy.
Eligibility criteria includes:
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at email@example.com
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to firstname.lastname@example.org
Subscribe for updates & stay in the loop with new studies.